Tags

Type your tag names separated by a space and hit enter

Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis.
Am J Gastroenterol 2008; 103(8):1966-72AJ

Abstract

BACKGROUND

While the likelihood of developing hepatocellular carcinoma (HCC) in patients coinfected with both HBV and HCV is increased, the role of previous exposure to HBV as a risk factor associated with tumor occurrence in subjects with HCV-related cirrhosis has not been fully investigated.

AIM

To assess whether serum anti-HBc positivity, as a marker of previous HBV exposure, is associated with HCC development in HCV-related positive, hepatitis B surface antigen (HBsAg) negative patients with cirrhosis treated with alfa-interferon (IFN) monotherapy. PATIENTS AND: A database including 883 consecutive patients (557 men, mean age 54.7 yr) with histologically

METHODS

proven cirrhosis treated with IFN between 1992 and 1997 was analyzed. All subjects have been surveilled every 6 months by ultrasound. Independent predictors of HCC were assessed by Cox multiple regression analysis.

RESULTS

Mean follow-up was 96.1 months. Anti-HBc testing was available in 693 cases and, among them, 303 patients (43.7%) were anti-HBc seropositive. Anti-HBc positive patients were more often men (67.0%vs 58.7%, P= 0.03), had lower transaminase levels (3.3 +/- 2.0 vs 3.8 +/- 2.5 u.l.n., P= 0.004), and had higher rate of alcohol intake (38.3%vs 22.5%, P < 0.001) than anti-HBc negative patients. Overall, the incidence rates of HCC per 100 person-years were 1.84 (95% CI 1.34-2.47) in the anti-HBc positive patients and 1.86 (95% CI 1.41-2.42) in anti-HBc negative ones. By Cox multiple regression, there was no association of serum anti-HBc with HCC development (HR 1.03, 95% CI 0.69-1.52) or liver-related deaths incidence (HR 1.21; 95% CI 0.76-1.95).

CONCLUSIONS

In comparison with anti-HBc negative subjects, serum anti-HBc positive patients with HCV-related/HBsAg negative cirrhosis treated with IFN monotherapy did not show a greater risk of HCC.

Authors+Show Affiliations

Department of Gastroenterology, Ospedale San Giacomo, Roma, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18637087

Citation

Stroffolini, Tommaso, et al. "Lack of Correlation Between Serum anti-HBcore Detectability and Hepatocellular Carcinoma in Patients With HCV-related Cirrhosis." The American Journal of Gastroenterology, vol. 103, no. 8, 2008, pp. 1966-72.
Stroffolini T, Almasio PL, Persico M, et al. Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis. Am J Gastroenterol. 2008;103(8):1966-72.
Stroffolini, T., Almasio, P. L., Persico, M., Bollani, S., Benvegnù, L., Di Costanzo, G., ... Bruno, S. (2008). Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis. The American Journal of Gastroenterology, 103(8), pp. 1966-72. doi:10.1111/j.1572-0241.2008.01912.x.
Stroffolini T, et al. Lack of Correlation Between Serum anti-HBcore Detectability and Hepatocellular Carcinoma in Patients With HCV-related Cirrhosis. Am J Gastroenterol. 2008;103(8):1966-72. PubMed PMID: 18637087.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis. AU - Stroffolini,Tommaso, AU - Almasio,Piero Luigi, AU - Persico,Marcello, AU - Bollani,Simona, AU - Benvegnù,Luisa, AU - Di Costanzo,Giovangiuseppe, AU - Pastore,Giuseppe, AU - Aghemo,Alessio, AU - Stornaiuolo,Gianfranca, AU - Mangia,Alessandra, AU - Andreone,Pietro, AU - Stanzione,Maria, AU - Mazzella,Giuseppe, AU - Saracco,Giorgio, AU - Del Poggio,Paolo, AU - Bruno,Savino, AU - ,, Y1 - 2008/07/12/ PY - 2008/7/19/pubmed PY - 2008/10/22/medline PY - 2008/7/19/entrez SP - 1966 EP - 72 JF - The American journal of gastroenterology JO - Am. J. Gastroenterol. VL - 103 IS - 8 N2 - BACKGROUND: While the likelihood of developing hepatocellular carcinoma (HCC) in patients coinfected with both HBV and HCV is increased, the role of previous exposure to HBV as a risk factor associated with tumor occurrence in subjects with HCV-related cirrhosis has not been fully investigated. AIM: To assess whether serum anti-HBc positivity, as a marker of previous HBV exposure, is associated with HCC development in HCV-related positive, hepatitis B surface antigen (HBsAg) negative patients with cirrhosis treated with alfa-interferon (IFN) monotherapy. PATIENTS AND: A database including 883 consecutive patients (557 men, mean age 54.7 yr) with histologically METHODS: proven cirrhosis treated with IFN between 1992 and 1997 was analyzed. All subjects have been surveilled every 6 months by ultrasound. Independent predictors of HCC were assessed by Cox multiple regression analysis. RESULTS: Mean follow-up was 96.1 months. Anti-HBc testing was available in 693 cases and, among them, 303 patients (43.7%) were anti-HBc seropositive. Anti-HBc positive patients were more often men (67.0%vs 58.7%, P= 0.03), had lower transaminase levels (3.3 +/- 2.0 vs 3.8 +/- 2.5 u.l.n., P= 0.004), and had higher rate of alcohol intake (38.3%vs 22.5%, P < 0.001) than anti-HBc negative patients. Overall, the incidence rates of HCC per 100 person-years were 1.84 (95% CI 1.34-2.47) in the anti-HBc positive patients and 1.86 (95% CI 1.41-2.42) in anti-HBc negative ones. By Cox multiple regression, there was no association of serum anti-HBc with HCC development (HR 1.03, 95% CI 0.69-1.52) or liver-related deaths incidence (HR 1.21; 95% CI 0.76-1.95). CONCLUSIONS: In comparison with anti-HBc negative subjects, serum anti-HBc positive patients with HCV-related/HBsAg negative cirrhosis treated with IFN monotherapy did not show a greater risk of HCC. SN - 1572-0241 UR - https://www.unboundmedicine.com/medline/citation/18637087/Lack_of_correlation_between_serum_anti_HBcore_detectability_and_hepatocellular_carcinoma_in_patients_with_HCV_related_cirrhosis_ L2 - http://Insights.ovid.com/pubmed?pmid=18637087 DB - PRIME DP - Unbound Medicine ER -